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829-5 Clinical Effects of Spinal Cord Stimulation in Patients 
With Refractory Angina Pectoris: Results From a 
Prospective Italian Registry 
Gaetano A. Lanza. Francesco DI Pede, Guerrino Zuin, Massimo Romanb, Dine Flap&i, 
Antonio Circa, Paola Cardano, Fulvio Bellocci, Ottavio Alfieri, Massimo Santini, Attilio 
Masen, for the Prospective Italian Registry of SCS for Refractory Angina, Roma, Italy 
Background. The treatment of patients with angma pectoris refractory to medical therapy 
and unsuitable for revascularization procedures is a challenging problem in the modern 
cardiology but it is not well standardized yet. Previous large retrospective studies and 
small prospective studies suggested beneficial effects of spinal cord stimutation (SCS) in 
these patients. 
Method. We organized a Prospective Multicenter Italian Registry of SCS to evaluate the 
short and long term clinical outcome of patients undergoing SCS device implantation 
because of severe refractmy angina pectoris and the clinical effects of this form of ther- 
apy. Patients were followed-up with periodic medical visits in out-patient clinics. 
Results. Overall, 104 patients were enrolled in the Registry (70 men, age 67.&17 years), 
most of whom (83%) had 3.vessel coronary artery disease. Average follow-up was 
13.2+7.9 months, ranging from 6 to 24 months. Overall, 17 patients (16.8%) died during 
the follow-up period, 8 (7.9%) of whom of cardtac death. Among clinical variables, only 
age was found to be significantly associated both with total mortality (p=O.O4) and car- 
diac mortality (P=O.O2) on Cox regression analysis. At the last follow-up, a significant 
improvement of angina1 symptoms (>50% reduction of weekly angina1 episodes, com- 
pared to baseline) was reported by 73.0% of patients, and the Canadian Cardiovacular 
Society class of angina was improved by ~1 class in 80.5% and by x2 classes in 
42.3% of patients. A relevant reduction in the rate of hospital admission and days spent 
in the hospital because of angina (pcO.0001 for both) was also observed. No life-threat- 
ening or clinically serious events were observed as related to the SCS treatment. 
Conclusions. Our prospective data show that SCS can be performed safely and is asso- 
ciated with a sustained improvement of angina1 symptoms in a relevant number of 
patients with refractory stable angina pectoris. suggesting that it should be seriously 
taken into account for the treatment of these patients. 
515 p.m. 
829-6 Excess of Mortality in Patients With Endothelial 
Dysfunction 
Tatsuaki Murakami. Kazuo Ohsato, Fukui Cardiovascular Center, Fukul, Japan 
Background: Although endothelial dysfunction (ED) is thought to contribute to athero- 
thrombogenic processes, the relationship between ED and mortality, an extreme medical 
endpoint, remains unknown. This study investigated whether ED has prognostic impacts. 
Methods: ED was graded by noninvasively ultrasonic measured reactive changes in 
lumen diameter of right brachial artery following transient occlusion for 5 minutes (FMD; 
flow-mediated endothelium-dependent vasodilation) in consecutive 518 ambulatory 
patients with suspected coronary altery disease. The enrolled patients were categorized 
into 3 groups according to the values of FMD, and their fatal events were prospectively 
followed-up for no less than 24 months. Results: For a mean follow-up period of 45 
months with 100% follow-up, the patients with severe endothelial dysfunction (FMD<4%; 
Group-L, n=174) more frequently resulted in cardiovascular death than those in Group-M 
with mild endothelial dysfunction (4%<FMDc8%, n=l71) and Group-H with preserved 
endothelial function (FMD 8% or more, n=l73)[by Kaplan-Meier analysis] and more fre- 
quently resulted in non-cardiovascular death. Cox proportional hazard model analyses 
showed that severe endothelial dysfunction was significantly associated with future car- 
dlovascular and non-cardiovascular death. Conclusion: These results suggest noninva- 
sive assessment of endothelial dysfunction predicts future fatal events and stratify 
patients who are at high risk or low risk of mortality 
Group-L Group-M Group-H Odds Ratio P-Value 
Cardiovascular Death 8 (4.6%) 1 (0.6%) 1 (0.6%) 9.85 0.035 
Non-Cardiovascular Death 7 (4.0%) 3 (1.7%) 1 (0.6%) 7.43 0.049 
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836-l Lack of Benefit From Cytokine Mobilized Stem Cell 
Therapy for Acute Myocardial Infarction in Nonhuman 
Primates 
Andrew E. Arai, Farooq Sheikh, Kwabena 0. Agyeman, Robert Hoyt, Vandana Sachdev. 
Xu-Xi Yu, Hong San, Mark Metzger, Cynthia Dunbar, Donald Orlic, National Institutes of 
Health, Bethesda, MD 
Background: Mobilization of stem cells with stem cell factor (SCF) and granulocyte-col- 
any-stimulating factor (G-CSF) resulted in myocardial regeneration, improved ventricular 
function, and Improved mortality in mice with acute myocardial Infarction (Ml). We 
hypothesized that either single therapy with G-CSF or combination therapy with SCFIG- 
CSF would result in myocardial regeneration m monkeys after MI. Methods: Rhesus 
monkeys were treated with G-CSF (n=7) or SCFIG-CSF (n=7) subcutaneously on 8 con- 
secutive days starting 4 days prior and continuing 3 days after Ml was induced by a 2- 
hour occlusion of the LAD. Control animals (n-7) had the same surgery and infarction but 
no cytokine therapy. Stem cell mobilization was confirmed by serial blood tests. Gadolin- 
ium enhanced MRI was performed before, 1 week after, 6 weeks after, and 12 weeks 
after Ml. Results: Circulating primitive CD34+ progenitor cells were highest for the SCF/ 
G-CSF group (71+/-27 cells/uL), intermediate for the G-CSF group (31+/-13 cellsiul). 
and minimal for the control group (2+/-2 cells/uL). Post-MI mortality was 71% in the SCF/ 
G-CSF group vs 14% in the G-CSF group (p=O.lO) and 29% in the control group 
(p=O.28). None of the SCF/G-CSF mortality was attributed to anaphylaris and all deaths 
occurred in the post-MI period. The infarct size averaged 30% of the left ventricle in the 
SCF/G-CSF group (n=2 survivors). 24% in the G-CSF group, and 21% in the control 
group. MRI indices of ventricular volumes and ejection fraction showed unfavorable but 
nonsignificant trends toward worse outcome in both treatment groups compared to con- 
trols. One week post-MI, LV ejection fraction averaged 49% (n=2 survivors), 49%, and 
58% in the SCFIG-CSF. G-CSF. and control groups respectively. Conclusions: The lack 
of favorable treatment trends and the unexpectedly high mortality in the SCFIG-CSF 
group despite excellent primitive cell mobilization raise concerns regarding cyiokine ther- 
apy in the peri-infarct period. Compared with a prior successful study in mice, the current 
protocol used rhesus monkeys, a repeffused Infarct model, and generally smaller infarc- 
tions. High white blood cell counts may have adversely affected reperfusion in the mon- 
keys. 
8:45 a.m. 
836-2 Matrix Metalloproteinase Inhibition Limits Remodeling 
and Regional Systolic Dysfunction but Not Myocyte 
Hypertrophy Following Myocardial Infarction 
Sunil Mankad. J. Thomas Peterson, Robert W. Biederman, Walter E. McGregor, 
Deborah Scalise, James A. Magovern, Xinqiang Han, Carol Stolarski, Brent Anderson, A. 
Martin Gerdes, Nathaniel Reichek. Richard P. Shannon, Allegheny General Hospital, 
Pittsburgh, PA 
Background: Myocardial matrix metalloproteinase (MMP) activity is increased after MI, 
but effects of MMP inhibition (MMPi) on LV systolic function, myocyie hypeltrophy, tumor 
necrosis factor (TNF). and nitric oxide synthase (NOS) are unclear. Methods: 1 day after 
anteroapical MI, sheep were randomized to MMPi (PDl66793-Pfizer, Inc; n=lO) or no 
therapy (Control; n=lO). Magnetic resonance imaging was performed before and 8 
weeks after Ml to quantify changes in LV end-systolic volume index, end-diastolic volume 
index. eiection fraction. LV mass index. and adiacent (within 2 cm of infarct) circumferen- 
tial strain (%S). Myocyle morphometry , Western analyses and immunohistochemistry 
were assessed at E-weeks oost-MI. Results: MMPi limited LV remodelina (see Table. 
‘p<O.Ol vs control), but no differences in adjacent myocyte hypertrophy were seen (cell 
volume: 3.4eO.6 vs 3.5eO.4 x 104um3; cell length: 157216 vs 157i8 urn; and cross-sec- 
tional area: 228+26 vs 227*27 ud ; p=ns for Control vs MMPi for all). MMPi was associ- 
ated with decreased adjacent constitutive NOS and increased adjacent inducible NOS. 
There was a trend towards decreased adjacent TNF with MMPi: 612*75 vs 749*73 den- 
sity units (~~0.2). Conclusion: MMPi attenuated LV remodeling and reduced adjacent 
myocardial systolic dysfunction post-MI. In contrast to renin-angiotensin blockade in this 
model, beneficial effects of MMPi were not associated with reduced adjacent myocyte 
hypertrophy. Effects of MMPi on regulatory cytokines may play a role. 
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LV Remodelmg Parameters: Change from Baseline 
End-diastolic End-systolic Ejection LV mass Adjacent 
volume index (ml/ volume index(ml/ Fraction index (gm/ %S (%) 
kg) kg) (%) kg) 
MM +0.4 zt 0.3 
Pi 
+0.5 * 0.2’ -13*4’ +0.1 * 0.2 -3ztl’ 




836-3 Functional Significance of Toll-Like Receptor-2 
Mediated Signaling in the Heart Following Acute 
Ischemia/lnfarction 
Arunims. Misra, Osamu Takeuchi. Shizuo Akira, Douglas Mann, Jesus Vallejo, Baylor 
College of Medicine, Houston, TX, Osaka University, Osaka, Japan 
Background: Toll-like receptors (TLRs) are phylogentically conserved pattern recogni- 
tion receptors that recognize conserved molecular patterns present in invading microor- 
ganisms. Recent studies have shown that TLRs also recognize specific epitopes or 
ligands expressed by injured or dying cells and that certain polymorphisms in humans 
may confer protection in the setting of heart disease. Given that TLR2mediated signal- 
ing activates pro-apoptotic pathways, and that inhibition of TLR2mediated signaling con- 
fers cytoprotectlon in certain cell types, we asked whether TLRP-mediated signaling 
influenced the extent of myocardial tissue injury following acute ischemia. 
Methods: Northern and Western blot analysis were used to detect the presence of TLRP 
in the adult murine heart. lmmunohistochemistry was used to localize TLRP in the heart. 
To determine the functional significance of TLRP, we performed permanent occlusions of 
the left anterior descending artery in littermate control and TLRP deficient mice. The 
extent of myocardial injury was assessed by lTC staining at 24hrs. 
Results: TLRP mRNA and protein were readily detected in the adult heart, and TLRP 
mRNA expression was increased following ischemia reperfusion injury. Moreover, TLRP 
was immunolocalized to cardiac myocytes. The extent of infarction by TTC staining was 
strikingly less (~~0.02) in the TLRP deficient mice when compared to littermate controls 
(23+4.3% vs 43t5.7%, respectively). 
Conclusions: The results show that TLRP expression is dynamically regulated in the 
heart and that TLR2-mediated signaling contributes importantly to the extent of myocar- 
dial injury following acute ischemia/infarction. These studies raise the interesting possi- 
bility that disruption of TLR2-mediated signaling may represent a novel therapeutic target 
in the setting of acute myocardial ischemia. 
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836-4 P-Selectin Blockade Attenuates Microvascular Platelet 
Deposition and Increases Myocardial Salvage After 
Reperfusion 
Jo& A. BarrabBs, David Garcia-Dorado, Maribel Mirabet, Javier Inserte, Luis AguIld, 
Bernat Soriano, Anna Massaguer, Ferran Padilla. Rosa M. Lid6n, Jordi Soler-Soler, 
Hospital Universitari Vail d’Hebron, Barcelona, Spain 
Background: The benefits of coronary reperfusion may be lhmited by platelet deposition 
at the microvasculature. Although it has been demonstrated that P-se&tin participates 
in this deposition, whether interfering with P-selectin-dependent adhesion reduces the 
magnitude of platelet-mediated myocardial damage after reperfusion remains unclear. 
Methods: Thiopental-anesthetized, open-chest pigs were blindly allocated to receive a 
continuous intravenous infusion of the selectin blocker fucoidan (30 pg/kg/min) or vehi- 
cle. Fifteen minutes after start of the infusion, animals were subjected to mechanical 
injury of the left anterior descending coronary artery followed by a 46.min occlusion. In 
20 pigs (10 per group), the heart was excised 2 h after reflow and the content of 99mTc- 
labeled platelets in large myocardial samples (2.9*1 g) was determined. In 16 separate 
animals (6 per group), the reperfusion period was extended to 4 h and infarct size was 
measured by the trypheniltetrazolium chloride reaction. The effect of fucoidan on reper- 
fused myocardium was also assessed in isolated, perfused rat hearts subjected to 40 
min of global ischemia and 60 min of reflow and receiving during the 5 min prior to 
lschemia an infusion of thrombin-activated platelets (2x106) plus neutrophils, wth (n=6) 
or without (n=6) fucoidan (30vg/ml). 
Results: Fucoidan did not modify P-selectin expression in circulating platelets or in 
thrombin-activated platelets. Compared to pigs receiving vehicle, those treated with 
fucoidan had less platelets in reperfused myocardium (23.3k3.3 vs. 42.1+6.3x106/g, 
respectively, PzO.03) and smaller infarcts (53+2 vs. 73*5% of the area at risk, respec- 
tively, P=O.O03). In isolated rat hearts, treatment with fucoldan was associated with 
increased left ventricular developed pressure, reduced end-diastolic pressure, and 
reduced LDH release (61+2 vs. 65*3 U/g, respectively, PcO.001) during the reperfusion 
period. 
Conclusion: The results strongly suggest that P-selectin-dependent adhesion is a promi- 
nent mechanism of platelet deposition in rep&used microvessels and that its antago- 
nism may enhance the benefits of coronary restoration of flow on myocardial salvage. 
9:30 a.m. 
836-5 Cardioselective Nitric Oxide Synthase 3 Gene Transfer 
Protects Against Myocardial Ischemia-Reperfusion 
Injury in Pigs 
Zsolt S&id, Peter Sinnaeve, Pieter Vermeersch, Hilde Gillijns, Marijke Pellens, 
Natascha Van Pelt, Peter Pokreisz, Erik Verbeken, Desire Collen, S&fan Janssens, 
Center for Transgene Technology and Gene Therapy, University of Leuven, Leuven. 
Belgium 
Background. Presewed endothelial NO Synthase (NOS3) gene function protects against 
ischemia-reperlusion injury (l/R) in mice. We investigated the effect of cardioselective 
NOS3 gene transfer on I/R injury in pigs. 
Methods. Retrograde coronary venous injection of adenoviral vectors carrying human 
NOS3 [AdNOSS, 5x10(10) PFU. n=9] or no transgene [AdRR5,5xlO(lO) PFU, n&3] was 
performed in anaesthetized pigs. After 3 days, mid-LAD was occluded by PTCA balloon 
inflation for 45 min followed by 4 h R. Left ventricular pressure and dP/dT were continu- 
ously monitored using a micro-tip Millar catheter and troponm I levels were determined. 
Infarct size was measured on transversal myocardial sections using viability surface 
staining, and leukocyte infiltration and apoptosis were determined using CD45 and 
caspase-3 immunostaining. 
Results. Area at risk (AAR) was similar in both groups. Myocardial infarct size was 
77*6% of AAR in AdRR5-injected, but only 31*7% of AAR in AdNOSB-treated pigs 
(PcO.05 versus AdRR5). Mean pre-ischemic dP/dT was similar in AdRRB- and AdNOSS- 
treated pigs (2980*114 mmHg/sec and 2722i96 mmHg/sec. respectively). Maximal dP/ 
dT significantly decreased from its pre-ischemic value at 30 min R I” AdRRS-treated pigs 
and remained depressed for 4 h (2071*50 mmHg/sec, P~O.003 versus baseline). In 
NOSBtreated pigs, however, no significant decrease was detected during R. By the end 
of R troponin I levels markedly increased but to a significantly lower degree in NOS3- 
than in AdRRS-treated pigs (132+15 mg/L versus 552~62 mg/L, respectively, PcO.05). 
The extent of CD45 positive inflammatory cell inflltration in the anterior wall was 39.4i4.3 
cells/mm2 in the AdRRS- versus 18.1+2.6 cells/mm2 in AdNOS3-treated animals 
(P<O.O005 YS AdRR5 group). Caspase-3 immunoreactivity in vascular cells was 
observed in 16.521.3 vessels/mm2 in AdRR5- versus in 4.921.3 vessels/mm2 in 
AdNOSS-treated pigs (P<O.O0005 vs AdRR5 pigs). 
Conclusions. Adenovirus-mediated myocardial NOS3 gene transfer attenuates MI/R 
injury in pigs. Decreased tissue infiltration of leukocytes and decreased vascular apop- 
totic cell death may contribute to the beneficial effects. 
9:45 a.m. 
836-6 Drug-Reducing Polymers Decrease Arterial Vascular 
Resistance Without Causing Vasodilation 
John J. Pacella, Marina V. Kameneva, David Fischer, Erxiong Lu, Melissa Csikari, 
Arkady Uryash, Flordeliza S. Villanueva, University of Pittsburgh Medical Center, 
Pittsburgh, PA 
Background: Flow resistance reduction by soluble high molecular weight drag-reducing 
polymers (DRPs) is a hydrodynamic phenomenon with potential biomedical applications. 
We have recently shown that the addition of DRPs in the setting of a flow-limiting coro- 
nary stenosis reduces coronary vascular resistance and increases flow in a canine 
model. Whether resistance reduction by DRPs is due to vasodilation or changes in fluid 
dynamics is unclear. Accordingly, ws tested the hypothesis that DRPs decrease vascular 
resistance independent of vasodilation. 
Methods: The effects of DRPs on flow/pressure relations were studled in a rabbit model 
(n=6) of adenosine (ADN)-induced maximal regional arterial vasodllation. Catheters were 
placed in the carotid artery and right femoral artery (FA) and vein (FV) for pressure mea- 
surement. A flow probe was placed on the left FA. After baseline measurements, ADN 
was infused into the left FA at doses to achieve regional maximal vasodilation (hypere- 
mia) without decreasing mean arterial pressure (MAP). Hemodynamic data were col- 
lected during ADN prior to and after intravenously infused DRP (Polyox WSR-301, 1 
ppm), and then after ADN was discontinued (DRP only). Vascular resistance was calcu- 
lated as (Mean FA-Mean FV Pressure)/Mean FA Flow. 
Results: During intra-arterial ADN, FA hyperemia was associated with a 44 * 27 % 
reduction in vascular resistance compared to baseline (p=O.O4). With DRP. there was an 
additional 22 * 15 % decrease in resistance (0.63 * 0.30 to 0.47 f 0.22 dyne-sec/cms, 
p=O.O4), a 26 * 21 % increase in FA flow (6.6 + 4.0 to 11.4 * 9.9 mUmin, p=O.O9), but no 
significant change in FA pressure (p=O.74). After discontinuation of ADN (DRP only), 
resistance remained 39 * 36 % below that at baseline (0.69 + 0.2 vs 1.1 f 0.4 dyne-sec.’ 
ems, p=0.07). 
Conclusions: Minute concentrations of DRPs reduce vascular resistance despite ADN- 
induced maximal vasodllation. This suggests that the mechanism of action of DRPs is 
not related to alterations in vasomotor tone, but to changes in the fluid dynamic proper- 
ties of blood. Altering fluid dynamics with DRPs may represent a new therapeutic 
approach for treating ischemia due to arterial stenoses. 
